Current progress in the development and use of artemether for chemoprophylaxis of major human schistosome parasites (Publications)
schistosomiasis, a chronic and debilitating parasitic disease of the tropics, is ranked second after malaria in terms of public health importance. At present, there is no vaccine available, and chemotherapy [...] with artemether, the methyl ether of dihydroartemisinin, already widely used for the treatment of malaria. The present article reviews the literature that led to the development of artemether for chemop
The potential of artemether for the control of schistosomiasis (Publications)
Schistosomiasis continues to rank - following malaria - at the second position of the world's parasitic diseases in terms of the extent of endemic areas and the number of infected people. There is yet [...] Interestingly, derivatives of artemisinin, which are already effectively used in the treatment of malaria, also exhibit antischistosomal properties. Significant advances have been made with artemether, the
Two successful decades of Swiss collaborations to develop new anti-malarials (Publications)
Over the last two decades there has been a renaissance in the pipeline of new drugs targeting malaria, with the launch of new products that help save the lives of children throughout the world. In addition [...] Third, the emergence of product-development-partnerships, in this case led by the Medicines for Malaria Venture, based in Geneva, has helped to catalyze the development of new medicines and bring the community
Improving methods for analysing anti-malarial drug efficacy trials: molecular correction based on length-polymorphic markers <em>msp</em>-1,... (Publications)
BACKGROUND: Drug efficacy trials monitor the continued efficacy of front-line drugs against falciparum malaria. Over-estimates of efficacy result in a country retaining a failing drug as first-line treatment [...] modelling to simulate parasite dynamics and genetic signals that occur in patients enrolled in malaria drug clinical trials. We compared estimates of treatment failure obtained from a selection of proposed
Inhibitors of Plasmepsin II-potential antimalarial agents (Publications)
In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results,
New 4-amino-2-azabicyclo[3.2.2]nonane derivatives and their antiprotozoal potencies (Publications)
East African sleeping sickness, Trypanosoma b. rhodesiense, and a protozoan parasite which causes Malaria tropica, Plasmodium falciparum K-1, a strain which is resistant to chloroquine and pyrimethamine
New 4-amino-2-azabicyclo[3.2.2]nonane derivatives and their antiprotozoal potencies (Publications)
East African sleeping sickness, Trypanosoma b. rhodesiense, and a protozoan parasite which causes Malaria tropica, Plasmodium falciparum K-1, a strain which is resistant to chloroquine and pyrimethamine
Inhibitors of Plasmepsin II-potential antimalarial agents (Publications)
In order to overcome the problem of drug resistance in malaria, it appears wise to concentrate drug discovery efforts toward new structural classes and new mechanisms of action. We report our results,
Long-lasting and fast-acting<em> in vivo</em> efficacious antiplasmodial azepanylcarbazole amino alcohol (Publications)
With approximately 429,000 deaths in 2016, malaria remains a major infectious disease where the need to treat the fever symptoms, but also to provide relevant post-treatment prophylaxis, is of major importance
Synthesis and evaluation of beta-carbolinium cations as new antimalarial agents based on pi-delocalized lipophilic cation (DLC) hypothesis (Publications)
efficacy. beta-Carbolinium compounds exhibit medium suppressive activity in vivo against rodent malaria
